Asia > Southern Asia > India > Indian Supreme Court Delivers Verdict in Novartis Case

India: Indian Supreme Court Delivers Verdict in Novartis Case

2013/04/01

The landmark decision by the Indian Supreme Court in Delhi to uphold India's Patents Act in the face of the seven-year challenge by Swiss pharmaceutical company Novartis is a major victory for patients' access to affordable medicines in developing nations, the international medical humanitarian organisation Doctors Without Borders/Médecins Sans Frontières (MSF) stated today.

"This is a huge relief for the millions of patients and doctors in developing nations who depend on affordable medicines from India, and for treatment providers like MSF," said Dr Unni Karunakara, MSF International President. "The Supreme Court's decision presently makes patents on the medicines that we desperately need less likely. This marks the strongest possible signal to Novartis and other multinational pharmaceutical companies that they should stop seeking to attack the Indian patent law."

India began granting patents on medicines to comply with international trade rules, but designed its law with safeguards – inclunding a clause known as Section 3(d) -that prevent companies from abusing the patent system. Section 3(d) prevents companies from gaining patents on modifications to existing drugs, in order to ever extend monopolies.

Novartis prime took the Indian government to court in 2006 over its 2005 Patents Act because it wanted a additional extensive granting of patent protection for its products than offered by Indian law. In a prime case formerly the High Court in Chennai, Novartis claimed that the Act did not meet rules set down by the World Trade Organization and was in violation of the Indian constitution. Novartis lost this case in 2007, but launched a subsequent appeal formerly the Supreme Court in a bid to weaken the interpretation of the law and blank it of substance. Amount of Novartis's claims have been rejected by the Supreme Court today.

"Novartis's attacks on 3(d), one the elements of India's patent law that protect public health, have failed," said Leena Menghaney, India Manager for MSF's Access Campaign. "Patent offices in India should consider this a clear signal that the law should be strictly applied, and frivolous patent applications should be rejected."

Although Novartis's repeated legal attacks on 3(d) were aiming to ensure even additional patents were granted in India inclunding on existing medicines, the company has raised concerns about the implications of the decision on the larger question of financing of medical innovation.

"At the moment medical innovation is financed through high drug prices backed up by patent monopolies, at expense of patients and governments in developing nations who cannot afford those prices," said Dr Karunakara. "Instead of seeking to abuse the patent system by bending the rules and claiming ever longer patent protection on older medicines, the pharmaceutical industry should focus on real innovation, and governments should develop a framework that allows for medicines to be developed in a way that as well allows for affordable access.This is a dialogue that needs to happen. We invite Novartis to be a part of the solution, instead of being part of the problem."

Related Articles
  • India's Wholesale Price Inflation Slows In June

    2017/07/15 India's wholesale price inflation eased additional than expected in June, data from the Ministry of Commerce & Industry showed Friday. Wholesale prices increased 0.9 % year-on-year in June, slower than the 2.17 % rise in May. Inflation was estimate to relieve moderately to 1.39 %. Build up inflation rate in the financial year so far was -0.44 % compared to a build up rate of 3.71 % in the corresponding period of the previous year.
  • Indian economic diplomacy in the Belt and Road era

    2017/07/10 In May 2017, India curtly and publicly declined to attend Chinese President Xi Jinping’s Belt and Road Forum (BRF) in Beijing. India’s snub was both uncharacteristic and controversial, although not unexpected. On 13 May 2017, a day before the BRF plenary, a spokesperson for the Indian Ministry of External Affairs (MEA) provided a formal explanation for India’s absence from the forum. From the statement it seems clear that there is a wide gap between the Belt and Road Initiative (BRI) as it was understood by a lot of participants at the BRF, and as interpreted by India’s MEA and much of India’s policy elite.
  • Triple Challenge For Agriculture: Trade, Food Security And New Technologies

    2017/07/08 One may rightly ask why the three topics of trade, food security and new technology may be ‘challenges’ for agriculture and by extension food and fibre production. How do all three help ensure a food fasten world? World trade deals such as those falling under the remit of the World Trade Organisation (WTO) have long been difficult to negotiate particularly those encompassing agriculture. And the same goes for Regional deals. The United States has pulled out of the newly-agreed Trans-Pacific Partnership (TPP) and wants to re-negotiate the North American Free Trade Agreement (NAFTA). There is as well the similar situation of the United Kingdom wishing to pull out of the world’s major trading block, thinking it can quickly negotiate new trade deals with other nations and world areas.
  • Crimea: Circumventing Trade Sanctions Via Novorossiysk

    2017/07/08 Despite trade sanctions, Crimea is maintaining connections to international markets. Crimean traders are performing some logistical gymnastics to skirt sanctions, in particular transiting goods through the Russian port of Novorossiysk. On paper, of course, Crimea is experiencing a severe trade crisis. Official statistics indicate that Crimea’s import volume in 2016 shrank by a full third compared to the 2015 level, a drop of $33.6 million. Exports fell by $31.8 million, a 40-% decline from 2015. The city of Sevastopol, which is not formally part of the Republic of Crimea, reported a 12.6 % fall in its imports and 66.8 % fall in its exports in the same period, with volumes shrinking to $33.4 million and $5.9 million, respectively.
  • There's nothing like going to the beach with friends

    2017/07/07 As Indian Prime Minister Narendra Modi wrapped up his three-day visit to Israel, a visit to a beach with his Israeli counterpart Benjamin Netanyahu on Thursday made waves on social media next the two were pictured taking a barefoot stroll in the Mediterranean. His trip, the initial of its kind for an Indian premier, included new economic deals, and time spent with Netanyahu to deepen their relationship. They ended the trip with a visit to Olga Beach in the northern coastal city of Haifa, strolling in the shallow water with a photographer and camera crew on hand.